Gilead Could Goose Biotech ETFs
Some well-known biotechnology exchange traded funds could be stirred by Gilead Sciences (GILD) fourth-quarter earnings report released Tuesday after the close of U.S. markets.The California-based company posted net income of $3.49 billion, or $2.18 a share, compared with $791 million, or 47 cents a share, a year earlier as revenue more than doubled to $7.31 billion from $3.12 billion on […]